Bayer HealthCare today announced that the U.S. Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam, 15% for the topical treatment of mild to moderate rosacea. The product has an affect on the rosacea’s inflammatory papules and pustules.

The approval is based on results from two clinical trials.

“The FDA approval of Finacea® Foam is the result of several years of research and development,” said James Robins, VP & General Manager, Bayer HealthCare Pharmaceuticals Inc. “Not only does it add to our current product line, it also demonstrates Bayer’s continued commitment to addressing the needs of patients with mild to moderate rosacea.”
Finacea Foam will be available by prescription only beginning in September 2015.